FDA delays decision on approval for wider use of Amarin's Vascepa

(Reuters) - Amarin Corp Plc said the U.S. Food and Drug Administration has informed the company that it would delay a decision on approval of a blood fat-lowering drug for use in a broader patient population. Amarin's shares rose 14 percent before the bell. The FDA was due to release its decision on approval of the drug, Vascepa, on Friday. Amarin appealed for a review, and the agency told the company that since the appeal remains under consideration it decided to take no action on the approval for expanded use.



via Health News Headlines - Yahoo News http://news.yahoo.com/fda-delays-decision-approval-wider-amarin-39-vascepa-121206342--finance.html